COMPARE
HDFC Pharma and Healthcare Fund - Growth Option - Direct Plan vs quant BFSI Fund - Growth Option - Direct Plan
HDFC Pharma and Healthcare Fund and quant BFSI Fund are both in the Sectoral/ Thematic category, from HDFC Asset Management Company Limited and quant Money Managers Limited respectively. HDFC Pharma and Healthcare Fund has posted a higher 3-year rolling CAGR. HDFC Pharma and Healthcare Fund has the lower expense ratio. See the full table and FAQ below for the complete real-data comparison.
Basics
HDFC Pharma and Healthcare Fund has the lower direct-plan expense ratio, by 0.92 percentage points.
| HDFC Pharma and Healthcare Fund - Growth Option - Direct Plan | quant BFSI Fund - Growth Option - Direct Plan | |
|---|---|---|
| Category | Sectoral/ Thematic | Sectoral/ Thematic |
| AMC | HDFC Asset Management Company Limited | quant Money Managers Limited |
| Benchmark | BSE Healthcare TRI | Nifty Financial Services TRI |
| NAV | ₹21.715 (2026-10-28) | ₹19.4632 (2026-10-28) |
| AUM | ₹3,431.831 Cr | ₹854.191 Cr |
| Expense Ratio (Direct) | 1.03% | 1.95% |
| Inception | 2023-09-14 | 2023-06-01 |
Returns
HDFC Pharma and Healthcare Fund leads on 3-year rolling CAGR (28.9% vs quant BFSI Fund's 22.8%) - see the FAQ below for percentile context within each fund's own category.
Risk Metrics
quant BFSI Fund has been the more volatile of the two by standard deviation.
| HDFC Pharma and Healthcare Fund - Growth Option - Direct Plan | quant BFSI Fund - Growth Option - Direct Plan | |
|---|---|---|
| 3Y Sharpe Ratio | 1.35 | 0.53 |
| 3Y Alpha | 8.0057% | 8.8665% |
| 3Y Std Deviation | 14.7512% | 17.9855% |
| 3Y Calmar Ratio | 1.80 | 0.75 |
Portfolio Analytics
HDFC Pharma and Healthcare Fund carries the higher portfolio P/E ratio (a rougher proxy for how richly the underlying holdings are valued) - see the table below for the full comparison.
| HDFC Pharma and Healthcare Fund - Growth Option - Direct Plan | quant BFSI Fund - Growth Option - Direct Plan | |
|---|---|---|
| P/E Ratio | 46.5908 | 11.7419 |
| P/B Ratio | 3.1405 | - |
| Dividend Yield | 0.413% | 1.5958% |
| Active Share | 39.96% | 97.37% |
| Portfolio Turnover | 4194% | - |
| YTM | - | 5.3279% |
| Duration (Macaulay) | - | - |
Punji Fund Health Score
HDFC Pharma and Healthcare Fund and quant BFSI Fund carry the same Punji Quality grade.
Frequently asked questions
Which has a higher 3-year return, HDFC Pharma and Healthcare Fund or quant BFSI Fund?
HDFC Pharma and Healthcare Fund's 3-year rolling CAGR of 28.9% is higher than quant BFSI Fund's 22.8%. HDFC Pharma and Healthcare Fund sits in the 99th percentile of its category on this metric, versus the 91st percentile for quant BFSI Fund - though note both funds may belong to different categories with different medians, so a raw CAGR comparison doesn't account for how each fund performed relative to its own peers. A higher historical return also doesn't necessarily mean lower risk; check the risk metrics below before concluding either fund is the "better" choice.
Which has a lower expense ratio, HDFC Pharma and Healthcare Fund or quant BFSI Fund?
HDFC Pharma and Healthcare Fund's direct-plan expense ratio is 0.92 percentage points lower than quant BFSI Fund's. Over long holding periods, a persistent expense-ratio gap compounds into a materially different final corpus even if the two funds' gross returns are similar - it's one of the few fund attributes you can compare with total certainty upfront, unlike future returns, since the fee is contractually fixed rather than a historical estimate.
Which fund carries more risk, HDFC Pharma and Healthcare Fund or quant BFSI Fund?
By standard deviation (a measure of how much a fund's returns swing around its own average), quant BFSI Fund has been more volatile than HDFC Pharma and Healthcare Fund over the trailing window. Standard deviation captures total volatility in both directions - up and down - so a higher figure means bigger swings generally, not necessarily bigger losses specifically. Sharpe ratio (1.35 for HDFC Pharma and Healthcare Fund vs 0.53 for quant BFSI Fund) is a better single measure of risk-adjusted return, since it weighs the return earned per unit of volatility taken rather than volatility alone.
Which has higher AUM, HDFC Pharma and Healthcare Fund or quant BFSI Fund?
HDFC Pharma and Healthcare Fund has ₹3,432 Cr in assets under management, versus ₹854 Cr for quant BFSI Fund. A larger AUM generally means deeper liquidity and lower per-unit fixed costs for the AMC to spread across investors, but an AUM that's very large relative to a fund's category and strategy (especially in small/mid cap categories, where the investable universe is smaller) can also make it harder for a manager to enter and exit positions without moving the price - bigger isn't automatically better, especially for less liquid categories.
Which fund has a longer track record, HDFC Pharma and Healthcare Fund or quant BFSI Fund?
quant BFSI Fund launched on 2023-06-01, making it older than HDFC Pharma and Healthcare Fund (launched 2023-09-14). A longer track record means more real market cycles (bull runs, corrections, rate cycles) the fund has actually navigated, which is useful context for judging consistency - but it isn't a guarantee of future performance, and a newer fund isn't automatically worse, especially if it's run by an experienced manager or team with a track record at a prior fund.
Data as of 2026-10-29. Source: AMFI disclosures via Punji. Not investment advice.